Abstract
TNBC is an aggressive and metastatic subtype of breast cancer in which TP53 mutation occurs frequently and is associated with particularly poor outcome. Mutations in TP53 can disrupt the intrinsic function of the tumor suppressor as well as acquire oncogenic gain-of-function (GOF) activities. However, little is known about its oncogenic GOF mediators and functions. Targeted therapy for TNBC patients is thus one of the most urgent needs in breast cancer therapeutics, and identifying genes that have synthetic lethal interactions with mutant TP53 may be a promising approach. In this chapter, we present procedures on sequential analysis of RNA-seq followed by high-throughput RNA interference screening (HTS-RNAi screening). This approach has been utilized to identify genes with synthetic lethality of mutant TP53, providing a promising strategy for the treatment of mutant TP53 in TNBC and determining its impact on tumorigenesis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Papa A, Caruso D, Tomao S, Rossi L, Zaccarelli E, Tomao F (2015) Triple-negative breast cancer: investigating potential molecular therapeutic target. Expert Opin Ther Targets 19:55–75
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434
Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI (2011) The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. Med Oncol 28:745–752
Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH (2012) CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43:364–373
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O’Donovan N et al (2017) Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer 140:234–246
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
Walerych D, Napoli M, Collavin L, Del Sal G (2012) The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33:2007–2017
Horigome E, Fujieda M, Handa T, Katayama A, Ito M, Ichihara A et al (2018) Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. Oncotarget 9:34554–34566
Coussens MJ, Corman C, Fischer AL, Sago J, Swarthout J (2011) MISSION LentiPlex pooled shRNA library screening in mammalian cells. J Vis Exp 58. https://doi.org/10.3791/3305
Sun J, Nishiyama T, Shimizu K, Kadota K (2013) TCC: an R package for comparing tag count data with robust normalization strategies. BMC Bioinformatics 14:219
Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG et al (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31–48
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rokudai, S. (2020). High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer. In: Vancurova, I., Zhu, Y. (eds) Immune Mediators in Cancer. Methods in Molecular Biology, vol 2108. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0247-8_25
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0247-8_25
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0246-1
Online ISBN: 978-1-0716-0247-8
eBook Packages: Springer Protocols